Rhumbline Advisers Enanta Pharmaceuticals Inc Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q4 2024

A detailed history of Rhumbline Advisers transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Rhumbline Advisers holds 37,091 shares of ENTA stock, worth $234,044. This represents 0.0% of its overall portfolio holdings.

Number of Shares
37,091
Previous 36,165 2.56%
Holding current value
$234,044
Previous $375,000 43.2%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 30, 2025
BUY
$5.75 - $12.99 $5,324 - $12,028
926 Added 2.56%
37,091 $213,000
Q3 2024

Nov 12, 2024
BUY
$10.05 - $16.54 $16,069 - $26,447
1,599 Added 4.63%
36,165 $375,000
Q2 2024

Aug 01, 2024
BUY
$11.43 - $17.02 $17,693 - $26,346
1,548 Added 4.69%
34,566 $448,000
Q1 2024

May 09, 2024
BUY
$10.08 - $17.46 $7,096 - $12,291
704 Added 2.18%
33,018 $576,000
Q4 2023

Feb 08, 2024
SELL
$8.18 - $10.78 $1,357 - $1,789
-166 Reduced 0.51%
32,314 $304,000
Q3 2023

Nov 09, 2023
SELL
$11.09 - $22.13 $357,807 - $714,002
-32,264 Reduced 49.83%
32,480 $362,000
Q2 2023

Aug 08, 2023
BUY
$20.68 - $39.85 $18,239 - $35,147
882 Added 1.38%
64,744 $1.39 Million
Q1 2023

May 11, 2023
BUY
$38.82 - $54.59 $147,477 - $207,387
3,799 Added 6.33%
63,862 $2.58 Million
Q4 2022

Feb 14, 2023
BUY
$40.77 - $53.73 $2,446 - $3,223
60 Added 0.1%
60,063 $2.79 Million
Q3 2022

Nov 10, 2022
BUY
$48.29 - $71.27 $203,928 - $300,973
4,223 Added 7.57%
60,003 $3.11 Million
Q2 2022

Aug 11, 2022
BUY
$38.13 - $76.93 $78,357 - $158,091
2,055 Added 3.83%
55,780 $2.64 Million
Q1 2022

May 12, 2022
SELL
$56.06 - $74.11 $23,040 - $30,459
-411 Reduced 0.76%
53,725 $3.82 Million
Q4 2021

Feb 10, 2022
SELL
$60.19 - $97.37 $61,634 - $99,706
-1,024 Reduced 1.86%
54,136 $4.05 Million
Q3 2021

Nov 12, 2021
SELL
$41.02 - $58.65 $278,771 - $398,585
-6,796 Reduced 10.97%
55,160 $3.13 Million
Q2 2021

Aug 05, 2021
SELL
$43.76 - $53.11 $177,796 - $215,785
-4,063 Reduced 6.15%
61,956 $2.73 Million
Q1 2021

May 06, 2021
BUY
$41.69 - $54.95 $31,767 - $41,871
762 Added 1.17%
66,019 $3.26 Million
Q4 2020

Feb 10, 2021
BUY
$41.16 - $47.47 $234,529 - $270,484
5,698 Added 9.57%
65,257 $2.75 Million
Q3 2020

Nov 12, 2020
SELL
$43.36 - $53.53 $90,362 - $111,556
-2,084 Reduced 3.38%
59,559 $2.73 Million
Q2 2020

Aug 13, 2020
BUY
$46.37 - $57.58 $172,218 - $213,852
3,714 Added 6.41%
61,643 $3.1 Million
Q1 2020

May 06, 2020
BUY
$40.22 - $62.0 $153,640 - $236,840
3,820 Added 7.06%
57,929 $2.98 Million
Q4 2019

Feb 05, 2020
BUY
$57.95 - $66.61 $186,599 - $214,484
3,220 Added 6.33%
54,109 $3.34 Million
Q3 2019

Oct 23, 2019
BUY
$60.08 - $88.17 $72,937 - $107,038
1,214 Added 2.44%
50,889 $3.06 Million
Q2 2019

Aug 14, 2019
BUY
$81.3 - $97.35 $225,770 - $270,340
2,777 Added 5.92%
49,675 $4.19 Million
Q1 2019

May 01, 2019
BUY
$69.08 - $105.66 $10,016 - $15,320
145 Added 0.31%
46,898 $4.48 Million
Q4 2018

Jan 31, 2019
BUY
$65.41 - $84.65 $570,506 - $738,317
8,722 Added 22.93%
46,753 $3.31 Million
Q3 2018

Nov 07, 2018
BUY
$85.46 - $126.37 $41,106 - $60,783
481 Added 1.28%
38,031 $3.25 Million
Q2 2018

Aug 06, 2018
BUY
$81.85 - $120.51 $56,558 - $83,272
691 Added 1.87%
37,550 $4.35 Million
Q1 2018

May 02, 2018
BUY
$57.91 - $92.15 $22,237 - $35,385
384 Added 1.05%
36,859 $2.98 Million
Q4 2017

Feb 09, 2018
BUY
$45.65 - $59.37 $204,329 - $265,740
4,476 Added 13.99%
36,475 $2.14 Million
Q3 2017

Nov 06, 2017
BUY
$37.91 - $46.8 $1.21 Million - $1.5 Million
31,999
31,999 $1.5 Million

Others Institutions Holding ENTA

# of Institutions
108
Shares Held
19.7M
Call Options Held
9.7K
Put Options Held
12.4K
View Full List

About ENANTA PHARMACEUTICALS INC

ENTA Quotes by TradingView
  • Ticker ENTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,724,900
  • Market Cap $131M
  • Description
  • Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...
More about ENTA
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email